步长制药：关于公司获得药品补充申请批准通知书的公告

Core Viewpoint - The company has received approval from the National Medical Products Administration for the supplementary application of a drug called Xiaolinbaituxian [2] Group 1 - The announcement was made on the evening of November 14 [2] - The approval pertains to the drug Xiaolinbaituxian, indicating a potential expansion in the company's product offerings [2]